Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that CEO Michael Halstead will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, in New York City. The presentation, set for September 14 at 9 a.m. EDT, will be webcast live, with a replay available on the company's investor relations website.
This appearance comes at a pivotal time for Helus Pharma, which is advancing its lead candidate, HLP003, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD). The drug has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, a status that can expedite development and review. Additionally, the company is conducting Phase 2 trials for HLP004, another proprietary NSA aimed at generalized anxiety disorder (GAD). These programs target significant unmet needs in mental health, where current treatments often have limitations in efficacy and onset of action.
The significance of the conference participation lies in the opportunity for Helus Pharma to communicate its scientific and clinical progress to the investment community. With the global mental health burden rising, the potential market for innovative therapies is substantial. According to the World Health Organization, depression affects over 264 million people worldwide, and many do not achieve remission with existing treatments. Helus Pharma's approach focuses on synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, which may offer more durable improvements.
Helus Pharma, which operates as the commercial name of Cybin Inc., founded in 2019, has a research portfolio extending beyond its lead candidates. The company is exploring other investigational NSAs, aiming to build a pipeline that addresses multiple psychiatric conditions. This breadth could position the company as a leader in the emerging field of neuroplasticity-based treatments.
The company's operations span Canada, the United States, the United Kingdom, and Ireland, providing a global footprint for clinical trials and potential commercialization. As Helus Pharma progresses through late-stage trials, the outcomes could have far-reaching implications for patients and the psychiatric pharmaceutical market.
The H.C. Wainwright conference is a prominent event where biotech and pharma companies present to investors, analysts, and potential partners. Participation offers visibility and a platform to discuss upcoming milestones, including data readouts and regulatory interactions. For Helus Pharma, this is a chance to highlight its progress and strategic vision.
Investors and industry observers will be watching closely for any updates on the Phase 3 program and the company's next steps. The live webcast and replay provide accessibility to a broad audience, ensuring that key stakeholders can stay informed about Helus Pharma's trajectory.
